TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31472684

Group type: EXPERIMENTAL
Intervention: 21-gene panel testing for mutations including BRCA1, BRCA2, CHEK2, PALB2, and others
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 21-gene panel testing for mutations
Number of subjects: 62
Study: 31473451

Group type: EXPERIMENTAL
Intervention: Passive ankle mobilization at 2°/s on both legs using a dynamometer
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Method 1 for calculating passive ankle joint stiffness
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Method 2 for calculating passive ankle joint stiffness
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Method 3 for calculating passive ankle joint stiffness
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Paretic values of passive ankle joint stiffness
Number of subjects: 13
Study: 31473727

Group type: EXPERIMENTAL
Intervention: Oral vitamin D 4000 IU/day for 6 months
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 85
Study: 31473943

Group type: EXPERIMENTAL
Intervention: Quizartinib hydrochloride (initial dose 20/30 mg/day)
Number of subjects: 0
Study: 31474223

Group type: EXPERIMENTAL
Intervention: BIA-guided dry weight adjustment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard clinical-guided dry weight adjustment
Number of subjects: 19
Study: 31474231

Group type: EXPERIMENTAL
Intervention: Food literacy education sessions on nutritional topics and practical activities
Number of subjects: 921
Study: 31474600

Group type: EXPERIMENTAL
Intervention: Conventional synthetic disease-modifying antirheumatic drugs and/or tumor necrosis factor inhibitors
Number of subjects: 571
Study: 31474848

Group type: EXPERIMENTAL
Intervention: Cognitive training with concurrent anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cognitive training with sham stimulation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cognitive training with concurrent anodal transcranial direct current stimulation (tDCS)
Number of subjects: 56
Study: 31475295

Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan treatment
Number of subjects: 794
Study: 31475856

Group type: EXPERIMENTAL
Intervention: hs-cTnl concentrations <5 ng/L
Number of subjects: 32837

Group type: EXPERIMENTAL
Intervention: hs-cTnl concentrations <2 ng/L
Number of subjects: 32837
Study: 31476851

Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin (BV) administered intravenously at 1.8 mg/kg every 3 weeks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin (BV)
Number of subjects: 33
Study: 31477052

Group type: EXPERIMENTAL
Intervention: Next generation sequencing of the T cell receptor (TCR) repertoire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed lymphocyte reaction between kidney donor and recipient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of TCR repertoire diversity and clonal expansion of T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tracking of alloreactive T cell clones
Number of subjects: 0
Study: 31477182

Group type: EXPERIMENTAL
Intervention: Distal phalangeal braided toenail flap
Number of subjects: 29
Study: 31477195

Group type: EXPERIMENTAL
Intervention: Selective attention impairment in MDD patients
Number of subjects: 1008
Study: 31477198

Group type: EXPERIMENTAL
Intervention: SSB intake at 5 years of age (100 ml/d increments)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: SSB intake at 5 years of age (categorical tertiles)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: SSB intake at 18 months of age
Number of subjects: 555
Study: 31477457

Group type: EXPERIMENTAL
Intervention: Cognitive assessment in African Americans with diabetes
Number of subjects: 0
Study: 31477479

Group type: EXPERIMENTAL
Intervention: Zenith Dissection Endovascular System (covered stent graft and bare metal stent)
Number of subjects: 73
Study: 31477781

Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) stove intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wood cooking
Number of subjects: 50
Study: 31477906

Group type: EXPERIMENTAL
Intervention: Low-affinity CD19 CAR T cell therapy
Number of subjects: 0
Study: 31478151

Group type: EXPERIMENTAL
Intervention: SPRInt exercise program plus Botulinum neurotoxin (BoNT)
Number of subjects: 15
Study: 31479702

Group type: EXPERIMENTAL
Intervention: Pembrolizumab with local therapy (stereotactic radiosurgery, surgery, or laser interstitial thermal therapy)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Pembrolizumab without local therapy
Number of subjects: 23
Study: 31480086

Group type: EXPERIMENTAL
Intervention: Laser surgery (90 infants) or bevacizumab (22 infants)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Untreated infants (211 infants)
Number of subjects: 323
Study: 31480291

Group type: EXPERIMENTAL
Intervention: Molecular profiling of gastric cancer
Number of subjects: 224
Study: 31481121

Group type: EXPERIMENTAL
Intervention: Low-dose post-transplant cyclophosphamide (14.5 mg/kg on days 3 and 4) with anti-thymocyte globulin (ATG)
Number of subjects: 239
Study: 31481367

Group type: EXPERIMENTAL
Intervention: CYPHP Evelina London model of care
Number of subjects: 90000

Group type: EXPERIMENTAL
Intervention: Mixed-methods process evaluation
Number of subjects: 90000

Group type: EXPERIMENTAL
Intervention: Quantitative analysis of routine clinical and administrative data
Number of subjects: 90000

Group type: EXPERIMENTAL
Intervention: Qualitative interviews and focus groups with stakeholders
Number of subjects: 90000

Group type: EXPERIMENTAL
Intervention: Policy review
Number of subjects: 90000
Study: 31481373

Group type: EXPERIMENTAL
Intervention: Management in low, middle, and high income countries (HICs)
Number of subjects: 0
Study: 31481506

Group type: EXPERIMENTAL
Intervention: Glycolytic tumors
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Metabolic classification based on glycolytic and cholesterogenic pathways
Number of subjects: 325
Study: 31481511

Group type: EXPERIMENTAL
Intervention: Galunisertib 150 mg twice daily for 14 days on/14 days off
Number of subjects: 41
Study: 31481566

Group type: EXPERIMENTAL
Intervention: Antirheumatic treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Socioeconomic status evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comorbidities and prescribed drugs identification
Number of subjects: 0
Study: 31481569

Group type: EXPERIMENTAL
Intervention: Intervention group undergoing modern revascularisation techniques
Number of subjects: 420

Group type: COMPARATOR
Intervention: Historical cohort
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Cardiac MRI and frailty assessments for patients aged ≥65 years undergoing intervention
Number of subjects: 420
Study: 31481633

Group type: EXPERIMENTAL
Intervention: Prolonged ICU stay (≥8 days)
Number of subjects: 674

Group type: COMPARATOR
Intervention: Short ICU stay (<8 days)
Number of subjects: 674
Study: 31481800

Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 55

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 55
Study: 31481889

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (CCT)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Combined training (COMB)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 140
Study: 31482242

Group type: EXPERIMENTAL
Intervention: Narrow wavelength excitation source (805-nm laser) added to conventional neurosurgical microscope
Number of subjects: 11
Study: 31482569

Group type: EXPERIMENTAL
Intervention: Galcanezumab (5 to 300 mg)
Number of subjects: 0
Study: 31482830

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) fitted intraorally at fixed 75% maximal protrusion
Number of subjects: 100
Study: 31482831

Group type: EXPERIMENTAL
Intervention: Poor sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 303
Study: 31482981

Group type: EXPERIMENTAL
Intervention: Secondary healing strategy using hydrofiber, n=4
Number of subjects: 16

Group type: COMPARATOR
Intervention: Primary closure of the wound, n=12
Number of subjects: 16
Study: 31483485

Group type: EXPERIMENTAL
Intervention: sipuleucel-T immunotherapy (3 biweekly infusions)
Number of subjects: 1976

Group type: EXPERIMENTAL
Intervention: sipuleucel-T immunotherapy
Number of subjects: 1976
Study: 31484461

Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors (PPIs)
Number of subjects: 646
Study: 31484498

Group type: EXPERIMENTAL
Intervention: HBB implementation
Number of subjects: 38078
Study: 31484632

Group type: EXPERIMENTAL
Intervention: Respiratory support at birth
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Tracheostomy
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Life-sustaining care
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Cause of death
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Tracheostomy status
Number of subjects: 145
Study: 31484667

Group type: EXPERIMENTAL
Intervention: GD2.CAR.15 (CD28-based construct with IL15)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GD2.CAR (CD28-based construct without IL15)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4-1BB-based constructs
Number of subjects: 0
Study: 31485239

Group type: EXPERIMENTAL
Intervention: C1-INH (SC) 60 IU/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 31485335

Group type: EXPERIMENTAL
Intervention: Intact cord resuscitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early cord clamping
Number of subjects: 0
Study: 31485435

Group type: EXPERIMENTAL
Intervention: Various treatments for prostate cancer including novel therapies
Number of subjects: 3636

Group type: EXPERIMENTAL
Intervention: Patient-reported quality-of-life measurement
Number of subjects: 3636

Group type: EXPERIMENTAL
Intervention: Medical resource utilization
Number of subjects: 3636

Group type: EXPERIMENTAL
Intervention: Disease status and outcome variables
Number of subjects: 3636
Study: 31485982

Group type: EXPERIMENTAL
Intervention: Colon cancer patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rectal cancer patients
Number of subjects: 0
Study: 31486377

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 851

Group type: COMPARATOR
Intervention: Men
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Women vs Men
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Mediators of highest pain in women vs men
Number of subjects: 851
Study: 31487218

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks
Number of subjects: 24
Study: 31487279

Group type: EXPERIMENTAL
Intervention: Acute dengue infections caused by DENV-1 and/or DENV-2
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Acute chikungunya infections
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Past dengue infections
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Past chikungunya infections
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Malaria Rapid Diagnostic Test
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Antimalarial treatment
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Antibacterial treatment
Number of subjects: 342
Study: 31487564

Group type: EXPERIMENTAL
Intervention: Lipid lowering therapy
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Prior ASCVD
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Markers of FH severity and conventional ASCVD risk factors
Number of subjects: 1900
Study: 31488093

Group type: EXPERIMENTAL
Intervention: MEG3 rs10132552
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: rs10132552 TC + CC
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: rs941576 AG + GG
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: MEG3 rs7158663
Number of subjects: 144
Study: 31488170

Group type: EXPERIMENTAL
Intervention: Client-centered intervention focusing on improving quality of family planning services, including counseling.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 0
Study: 31488216

Group type: EXPERIMENTAL
Intervention: HuMax-IL8 (BMS-986253) administered IV every 2 weeks at doses of 4, 8, 16, or 32 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HuMax-IL8 (BMS-986253) administered IV every 2 weeks
Number of subjects: 15
Study: 31488227

Group type: EXPERIMENTAL
Intervention: RESOLVE plus treatment as usual (TAU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 40
Study: 31488469

Group type: EXPERIMENTAL
Intervention: Immediate postpartum haemorrhage (PPH) management according to French guidelines, assessed through various self-completed questionnaires including PDPSI, STAI-Y-A, STAI-Y-B, M.I.N.I. 5.0.0, EPDS, GAD-7, IES-R.
Number of subjects: 1542

Group type: COMPARATOR
Intervention: Women without PPH (unexposed)
Number of subjects: 1542
Study: 31488473

Group type: EXPERIMENTAL
Intervention: Self-reported preventive measures and management strategies for knee symptoms (including non-pharmacological treatments and CAM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of healthcare system and surgical procedures
Number of subjects: 0
Study: 31489199

Group type: EXPERIMENTAL
Intervention: Sepsis-3 criteria
Number of subjects: 1081

Group type: COMPARATOR
Intervention: MARS-sepsis criteria
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: ICU-acquired infection
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: Hospital mortality for MARS-sepsis criteria
Number of subjects: 1081

Group type: COMPARATOR
Intervention: Hospital mortality for sepsis-3 criteria
Number of subjects: 1081
Study: 31490268

Group type: EXPERIMENTAL
Intervention: Dabigatran (110 mg bid)
Number of subjects: 851
Study: 31490308

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid with lidocaine, injected with a blunt-tip microcannula
Number of subjects: 60
Study: 31491565

Group type: EXPERIMENTAL
Intervention: Partial medial meniscectomy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Medial meniscus repair
Number of subjects: 56

Group type: COMPARATOR
Intervention: No medial meniscus involvement
Number of subjects: 56
Study: 31491604

Group type: COMPARATOR
Intervention: Primary tumours
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Metastatic tumours
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: CS conversion
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: IS conversion
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: CS-converted metastases
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: IS-converted metastases
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Hormone receptor-positive and HER2-positive tumours
Number of subjects: 57
Study: 31492151

Group type: EXPERIMENTAL
Intervention: Social work intervention recommended for 40% of patients after in-depth analysis
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Nikolaus-score (social situation)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Professional social support
Number of subjects: 57

Group type: COMPARATOR
Intervention: Long-term support after discharge
Number of subjects: 57

Group type: COMPARATOR
Intervention: Unmet needs in long-term aftercare
Number of subjects: 57
Study: 31492456

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Low phase angle
Number of subjects: 110
Study: 31492778

Group type: EXPERIMENTAL
Intervention: Depression or anxiety status evaluated with Patient Health Questionnaire-9 or Generalised Anxiety Disorder-7 Assessment scales during follow-up.
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Antidepression or antianxiety treatment among patients with ACS who received treatment after PCI.
Number of subjects: 5000
Study: 31492791

Group type: EXPERIMENTAL
Intervention: Comprehensive prevention programme including a computerized triage algorithm, waiting room patient call system, signage, educational messages, presence of a mediator, and video surveillance.
Number of subjects: 22107

Group type: EXPERIMENTAL
Intervention: Comprehensive prevention programme implemented in the first month of the intervention period.
Number of subjects: 22107
Study: 31492795

Group type: EXPERIMENTAL
Intervention: CNSDs for ≥4 weeks
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Age 75-84
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Age ≥85
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Polypharmacy
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Secondary education
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Concurrent use of ≥2 CNSDs
Number of subjects: 246
Study: 31492798

Group type: EXPERIMENTAL
Intervention: Isokinetic back muscle strength
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lumbar paraspinal muscle quantity and quality
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Conventional sarcopenic indices
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Spinal sagittal balance
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Back performance scale
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sorenson test
Number of subjects: 120
Study: 31492988

Group type: EXPERIMENTAL
Intervention: 5-FU-based combination chemotherapy
Number of subjects: 3223
Study: 31493051

Group type: EXPERIMENTAL
Intervention: Infected Mesh (IM) group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clean Control (CC) group
Number of subjects: 80
Study: 31493163

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg every 2 weeks
Number of subjects: 181
Study: 31493238

Group type: EXPERIMENTAL
Intervention: DAAs
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Baveno and expanded-Baveno criteria
Number of subjects: 247
Study: 31493319

Group type: EXPERIMENTAL
Intervention: Smartphone app
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Smart band
Number of subjects: 160
Study: 31493324

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with adults with SMI and diabetes, their relatives and friends, and health care staff.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of electronic primary care health records from the Clinical Practice Research Datalink (CPRD GOLD).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Merging findings from both qualitative interviews and health records analysis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommendations for interventions and services developed through co-design workshops.
Number of subjects: 0
Study: 31493591

Group type: EXPERIMENTAL
Intervention: Severe Sleep Apnea (SA)
Number of subjects: 553

Group type: COMPARATOR
Intervention: Nonsevere Sleep Apnea (SA)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Overall population (both severe and nonsevere SA)
Number of subjects: 553
Study: 31494135

Group type: EXPERIMENTAL
Intervention: Temporary single, fully covered self-expanding metal stent (FCSEMS) placement with scheduled removal at 10 to 12 months.
Number of subjects: 118
Study: 31494181

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX × 6 cycles, followed by radiation therapy (50 Gy in 25 fractions) concurrent with fixed-dose rate gemcitabine (1 g/m2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Resected patients (all R0)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 25
Study: 31494295

Group type: EXPERIMENTAL
Intervention: Fecal short-chain fatty acids during pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31494512

Group type: EXPERIMENTAL
Intervention: Effortful control
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Attentional control
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Inhibitory control
Number of subjects: 105

Group type: COMPARATOR
Intervention: Behaviorally-indexed child anxiety severity
Number of subjects: 105
Study: 31495483

Group type: EXPERIMENTAL
Intervention: Scoliotic deformity observed in patients with Friedreich ataxia
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Mean Cobb angle measurement
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Hyperkyphosis measurement
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Anterior misalignment measurement
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Surgical intervention (arthrodesis)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Correlation of Cobb angle with FA severity scores
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Posterior fusion surgery
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Loss of ambulation and spinal surgery
Number of subjects: 66
Study: 31495595

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM booster dose
Number of subjects: 701
Study: 31496362

Group type: EXPERIMENTAL
Intervention: Six-minute walking test (6MWT) for pwMS
Number of subjects: 49

Group type: COMPARATOR
Intervention: Six-minute walking test (6MWT) for HC
Number of subjects: 49
Study: 31496462

Group type: EXPERIMENTAL
Intervention: Self-referral to internet-delivered treatment
Number of subjects: 255

Group type: COMPARATOR
Intervention: Clinician-referral to face-to-face treatment
Number of subjects: 255
Study: 31496644

Group type: EXPERIMENTAL
Intervention: 0.01 mL (40 μg) intravitreal dexamethasone solution
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.03 mL (120 μg) intravitreal dexamethasone solution
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.05 mL (200 μg) intravitreal dexamethasone solution
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone solution
Number of subjects: 27
Study: 31496994

Group type: EXPERIMENTAL
Intervention: Carbohydrate Loading followed by High Carbohydrate Intake during Prolonged Physical Exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31497072

Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Number of subjects: 187

Group type: COMPARATOR
Intervention: Nonspecific taping (Control)
Number of subjects: 187
Study: 31498135

Group type: EXPERIMENTAL
Intervention: Upper limb (UL) robotic motor assessment protocol
Number of subjects: 69
Study: 31498564

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily (D3-32)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg single oral doses (D1 and D31)
Number of subjects: 2
Study: 31499373

Group type: EXPERIMENTAL
Intervention: Acute phase treatment
Number of subjects: 9898